Activist investor Altai Capital Management has formally called on OraSure Technologies, Inc. to explore a strategic sale, asserting that the medical device manufacturer could be worth significantly more to an acquirer than as a standalone entity. In a letter addressed to the board, Altai Capital Management President and Chief Investment Officer Rishi Bajaj suggested that the company could fetch a valuation double its current share price through a formal sale process.
OraSure is worth significantly more in a sale than as a standalone company.
